BSX
ACHAT TOTAL: 196 562 titres (~9 486 038,29 $ US)
- Insiders
- Morano Susan E, Habiger David C, Mahoney Michael F, LUDWIG EDWARD J
- Total bought
- $9,486,038
- Total sold
- —
- Last activity
- 2026-08-25
- Last synced
-
2026-08-31 10:14:36
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Neutral signal Scored 2026-08-30
BSX exhibits genuinely strong financial fundamentals with robust margin expansion and improving cash flow, supported by solid liquidity (80) and fundamental trend (85) scores.
The first sentence of the analysis written for BSX on 2026-08-30 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 69.0% | 61.3% | 62.0% | 60.8% | 62.8% | |
| Ebit Margin | 18.6% | 15.9% | 15.8% | 12.7% | 12.0% | |
| Ebitda Margin | 25.4% | 23.5% | 24.2% | 21.6% | 21.2% | |
| Operating Profit Margin | 19.8% | 15.7% | 15.3% | 14.4% | 16.2% | |
| Pretax Profit Margin | 16.9% | 13.6% | 13.9% | 9.0% | 9.1% | |
| Continuous Operations Profit Margin | 14.4% | 11.0% | 11.2% | 5.5% | 8.7% | |
| Net Profit Margin | 14.4% | 11.1% | 11.2% | 5.5% | 8.7% | |
| Bottom Line Profit Margin | 14.4% | 11.1% | 11.0% | 5.1% | 8.3% | |
| Current Ratio | 1.617 | 1.081 | 1.320 | 1.515 | 1.478 | |
| Quick Ratio | 1.076 | 0.642 | 0.817 | 1.024 | 1.101 | |
| Solvency Ratio | 0.222 | 0.180 | 0.179 | 0.123 | 0.137 | |
| Cash Ratio | 0.376 | 0.065 | 0.175 | 0.244 | 0.450 | |
| Price To Earnings Ratio | 48.648 | 70.889 | 53.503 | 103.097 | 61.343 | |
| Price To Earnings Growth Ratio | 0.876 | 4.267 | 0.380 | -2.930 | -0.064 | |
| Forward Price To Earnings Growth Ratio | 0.876 | 4.267 | 0.380 | -2.930 | -0.064 | |
| Price To Earnings Diluted Ratio | 49.149 | 71.456 | 53.887 | 103.768 | 61.834 | |
| Price To Earnings Diluted Growth Ratio | 0.890 | 4.326 | 0.383 | -2.957 | -0.065 | |
| Price To Book Ratio | 5.825 | 6.037 | 4.356 | 3.766 | 3.635 | |
| Price To Sales Ratio | 7.032 | 7.848 | 5.899 | 5.219 | 5.082 | |
| Price To Free Cash Flow Ratio | 38.588 | 49.692 | 49.324 | 72.417 | 45.911 | |
| Price To Operating Cash Flow Ratio | 31.133 | 38.263 | 33.559 | 43.374 | 32.310 | |
| Debt To Assets Ratio | 0.284 | 0.283 | 0.270 | 0.286 | 0.293 | |
| Debt To Equity Ratio | 0.512 | 0.512 | 0.492 | 0.528 | 0.569 | |
| Debt To Capital Ratio | 0.339 | 0.339 | 0.330 | 0.346 | 0.362 | |
| Long Term Debt To Capital Ratio | 0.321 | 0.289 | 0.308 | 0.336 | 0.346 | |
| Financial Leverage Ratio | 1.802 | 1.810 | 1.822 | 1.848 | 1.939 | |
| Working Capital Turnover Ratio | 10.358 | 15.934 | 8.050 | 6.341 | 4.703 | |
| Operating Cash Flow Ratio | 0.834 | 0.537 | 0.507 | 0.401 | 0.438 | |
| Operating Cash Flow Sales Ratio | 0.226 | 0.205 | 0.176 | 0.120 | 0.157 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.807 | 0.770 | 0.680 | 0.599 | 0.704 | |
| Debt Service Coverage Ratio | 6.245 | 1.618 | 3.811 | 4.748 | 4.069 | |
| Interest Coverage Ratio | 11.378 | 6.809 | 8.018 | 3.931 | 5.507 | |
| Short Term Operating Cash Flow Coverage Ratio | 11.656 | 1.932 | 4.714 | 76.300 | 7.165 | |
| Operating Cash Flow Coverage Ratio | 0.365 | 0.308 | 0.264 | 0.164 | 0.198 | |
| Capital Expenditure Coverage Ratio | 5.176 | 4.348 | 3.129 | 2.493 | 3.375 | |
| Dividend Paid And Capex Coverage Ratio | 5.176 | 4.348 | 3.023 | 2.288 | 3.071 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.018 | 0.079 | 0.053 | |
| Enterprise Value Multiple | 29.700 | 36.101 | 26.824 | 27.196 | 26.984 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 69.0% | ▲7.7% | ▲5.8% |
| Ebit Margin | 18.6% | ▲2.7% | ▲3.6% |
| Ebitda Margin | 25.4% | ▲1.9% | ▲2.2% |
| Operating Profit Margin | 19.8% | ▲4.0% | ▲3.5% |
| Pretax Profit Margin | 16.9% | ▲3.2% | ▲4.4% |
| Continuous Operations Profit Margin | 14.4% | ▲3.4% | ▲4.2% |
| Net Profit Margin | 14.4% | ▲3.3% | ▲4.2% |
| Bottom Line Profit Margin | 14.4% | ▲3.3% | ▲4.4% |
| Current Ratio | 1.617 | ▲0.535 | ▲0.215 |
| Quick Ratio | 1.076 | ▲0.433 | ▲0.144 |
| Solvency Ratio | 0.222 | ▲0.042 | ▲0.054 |
| Cash Ratio | 0.376 | ▲0.311 | ▲0.114 |
| Price To Earnings Ratio | 48.648 | ▼-22.241 | ▼-18.848 |
| Price To Earnings Growth Ratio | 0.876 | ▼-3.392 | ▲0.370 |
| Forward Price To Earnings Growth Ratio | 0.876 | ▼-3.392 | ▲0.370 |
| Price To Earnings Diluted Ratio | 49.150 | ▼-22.306 | ▼-18.869 |
| Price To Earnings Diluted Growth Ratio | 0.890 | ▼-3.436 | ▲0.375 |
| Price To Book Ratio | 5.825 | ▼-0.212 | ▲1.101 |
| Price To Sales Ratio | 7.032 | ▼-0.816 | ▲0.816 |
| Price To Free Cash Flow Ratio | 38.588 | ▼-11.103 | ▼-12.598 |
| Price To Operating Cash Flow Ratio | 31.133 | ▼-7.130 | ▼-4.595 |
| Debt To Assets Ratio | 0.284 | ▲0.001 | ▲0.001 |
| Debt To Equity Ratio | 0.512 | ▲0.000 | ▼-0.010 |
| Debt To Capital Ratio | 0.339 | ▲0.000 | ▼-0.004 |
| Long Term Debt To Capital Ratio | 0.321 | ▲0.032 | ▲0.001 |
| Financial Leverage Ratio | 1.802 | ▼-0.007 | ▼-0.042 |
| Working Capital Turnover Ratio | 10.358 | ▼-5.576 | ▲1.281 |
| Operating Cash Flow Ratio | 0.834 | ▲0.297 | ▲0.290 |
| Operating Cash Flow Sales Ratio | 0.226 | ▲0.021 | ▲0.049 |
| Free Cash Flow Operating Cash Flow Ratio | 0.807 | ▲0.037 | ▲0.095 |
| Debt Service Coverage Ratio | 6.245 | ▲4.628 | ▲2.147 |
| Interest Coverage Ratio | 11.378 | ▲4.569 | ▲4.250 |
| Short Term Operating Cash Flow Coverage Ratio | 11.655 | ▲9.724 | ▼-8.698 |
| Operating Cash Flow Coverage Ratio | 0.365 | ▲0.057 | ▲0.105 |
| Capital Expenditure Coverage Ratio | 5.176 | ▲0.828 | ▲1.472 |
| Dividend Paid And Capex Coverage Ratio | 5.176 | ▲0.828 | ▲1.595 |
| Dividend Payout Ratio | 0.000 | 0.000 | ▼-0.030 |
| Enterprise Value Multiple | 29.700 | ▼-6.402 | ▲0.339 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $141.16B | $131.43B | $84.00B | $66.19B | $60.42B | |
| Enterprise value | $151.53B | $142.17B | $92.62B | $74.54B | $67.95B | |
| EV / Sales | 7.55x | 8.49x | 6.50x | 5.88x | 5.71x | |
| EV / Op. cash flow | 33.42x | 41.39x | 37.01x | 48.85x | 36.33x | |
| EV / Free cash flow | 41.42x | 53.75x | 54.39x | 81.56x | 51.63x | |
| EV / EBITDA | 29.70x | 36.10x | 26.82x | 27.20x | 26.98x | |
| Net debt / EBITDA | 2.03x | 2.73x | 2.50x | 3.05x | 2.99x | |
| Current ratio | 1.62x | 1.08x | 1.32x | 1.51x | 1.48x | |
| Income quality | 1.57x | 1.86x | 1.57x | 2.19x | 1.80x | |
| Graham number | $27 | $20 | $18 | $12 | $14 | |
| Graham net-net | -$9 | -$9 | -$8 | -$8 | -$8 | |
| Tax burden | 85.3% | 81.2% | 80.3% | 61.2% | 96.7% | |
| Interest burden | 90.7% | 85.5% | 87.9% | 71.1% | 75.5% | |
| Working capital | $3.35B | $521.0M | $1.58B | $1.96B | $2.04B | |
| Invested capital | $33.16B | $28.04B | $25.27B | $23.61B | $22.84B | |
| Return on assets | 6.6% | 4.7% | 4.5% | 2.1% | 3.2% | |
| Operating ROA | 9.6% | 7.1% | 6.5% | 5.6% | 6.1% | |
| Return on tangible assets | 15.7% | 11.9% | 10.8% | 5.1% | 7.4% | |
| Return on equity | 11.9% | 8.5% | 8.3% | 4.0% | 6.3% | |
| Return on invested capital | 8.8% | 6.1% | 5.7% | 3.9% | 6.6% | |
| Return on capital employed | 10.4% | 8.0% | 7.2% | 6.4% | 6.9% | |
| Earnings yield | 2.0% | 1.4% | 1.9% | 1.1% | 1.7% | |
| Free cash flow yield | 2.6% | 2.0% | 2.0% | 1.4% | 2.2% | |
| Capex / Op. cash flow | 19.3% | 23.0% | 32.0% | 40.1% | 29.6% | |
| Capex / Depreciation | 64.0% | 62.3% | 66.9% | 53.9% | 50.7% | |
| Capex / Sales | 4.4% | 4.7% | 5.6% | 4.8% | 4.7% | |
| SG&A / Sales | 34.3% | 35.7% | 36.4% | 35.6% | 36.1% | |
| R&D / Sales | 10.2% | 9.6% | 9.9% | 10.4% | 10.1% | |
| Stock comp / Sales | 1.5% | 1.6% | 1.6% | 1.7% | 1.6% | |
| Intangibles / Total assets | 57.9% | 60.3% | 58.0% | 58.0% | 56.2% | |
| Days sales outstanding | 53d | 56d | 57d | 57d | 55d | |
| Days payables outstanding | 67d | 54d | 64d | 63d | 65d | |
| Operating cycle | 226d | 214d | 225d | 194d | 187d | |
| Cash conversion cycle | 159d | 160d | 161d | 131d | 122d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+7.4%EV / Sales ▼-11.1%EV / EBITDA ▼-17.7%EV / Op. cash flow ▼-7.967Earnings yield ▲+0.006Graham number ▲+6.316
Profitability
Return on equity ▲+0.034Return on assets ▲+0.019Return on invested capital ▲+0.027Return on capital employed ▲+0.024Operating ROA ▲+0.025Income quality ▼-0.293Tax burden ▲+0.040
Efficiency
Days sales outstanding ▼-2.549Days payables outstanding ▲+13.047Operating cycle ▲+11.903Cash conversion cycle ▼-1.144Capex / Sales ▼-0.004R&D / Sales ▲+0.006
Balance-sheet strength
Current ratio ▲+0.535Net debt / EBITDA ▼-0.692Working capital ▲+2834000000.000Invested capital ▲+5120000000.000Intangibles / Total assets ▼-0.024
Change over 5 years
Valuation
Market cap ▲+133.6%EV / Sales ▲+32.1%EV / EBITDA ▲+10.1%EV / Op. cash flow ▼-2.914Earnings yield ▲+0.003Graham number ▲+12.929
Profitability
Return on equity ▲+0.057Return on assets ▲+0.034Return on invested capital ▲+0.022Return on capital employed ▲+0.035Operating ROA ▲+0.035Income quality ▼-0.229Tax burden ▼-0.114
Efficiency
Days sales outstanding ▼-1.388Days payables outstanding ▲+1.657Operating cycle ▲+38.601Cash conversion cycle ▲+36.944Capex / Sales ▼-0.003R&D / Sales ▲+0.001
Balance-sheet strength
Current ratio ▲+0.139Net debt / EBITDA ▼-0.956Working capital ▲+1312000000.000Invested capital ▲+10321000000.000Intangibles / Total assets ▲+0.018
Employee count
Peer market caps
Congressional trades
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2026-07-07 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2026-06-05 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2026-06-05 | Gilbert Cisneros | Sale | $1,001 - $15,000 |
| 2026-06-02 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2026-05-29 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2026-05-19 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2026-05-11 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2026-03-30 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2026-03-27 | Michael McCaul | Purchase | $1,001 - $15,000 |
| 2026-02-10 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2026-01-30 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2025-12-24 | Gilbert Cisneros | Sale (Partial) | $1,001 - $15,000 |
| 2025-11-18 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2025-10-28 | Kevin Hern | Sale | $15,001 - $50,000 |
| 2025-10-17 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2025-10-07 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2025-09-23 | Valerie Hoyle | Sale (Full) | $1,001 - $15,000 |
| 2025-08-04 | Lisa McClain | Sale | $1,001 - $15,000 |
| 2025-07-31 | Gilbert Cisneros | Sale | $1,001 - $15,000 |
| 2025-06-26 | Gilbert Cisneros | Sale | $1,001 - $15,000 |
| 2025-06-11 | Gilbert Cisneros | Sale | $1,001 - $15,000 |
| 2025-05-13 | Gilbert Cisneros | Sale | $1,001 - $15,000 |
| 2025-05-13 | Gilbert Cisneros | Sale (Partial) | $1,001 - $15,000 |
| 2025-05-12 | Jefferson Shreve | Sale | $15,001 - $50,000 |
| 2025-04-28 | Gilbert Cisneros | Sale | $1,001 - $15,000 |
| 2025-04-21 | Bruce Westerman | Sale | $1,001 - $15,000 |
| 2025-03-17 | Gilbert Cisneros | Sale (Partial) | $1,001 - $15,000 |
| 2025-03-03 | Bruce Westerman | Purchase | $1,001 - $15,000 |
| 2025-02-24 | Gilbert Cisneros | Sale | $1,001 - $15,000 |
| 2024-12-11 | Lisa McClain | Purchase | $1,001 - $15,000 |
| 2024-10-29 | Valerie Hoyle | Purchase | $1,001 - $15,000 |
| 2024-01-10 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-12-04 | John Curtis | Sale | $1,001 - $15,000 |
| 2023-11-03 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-10-31 | Michael McCaul | Sale | $50,001 - $100,000 |
| 2023-10-31 | Michael McCaul | Purchase | $15,001 - $50,000 |
| 2023-10-31 | Michael McCaul | Purchase | $15,001 - $50,000 |
| 2023-10-31 | Michael McCaul | Sale | $15,001 - $50,000 |
| 2023-10-27 | Michael McCaul | Sale | $15,001 - $50,000 |
| 2023-10-27 | Michael McCaul | Sale | $50,001 - $100,000 |
| 2023-10-18 | Michael McCaul | Purchase | $15,001 - $50,000 |
| 2023-10-18 | Michael McCaul | Purchase | $50,001 - $100,000 |
| 2023-10-17 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-10-10 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-10-02 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-09-08 | Lois Frankel | Sale | $1,001 - $15,000 |
| 2023-05-31 | Lois Frankel | Sale (Partial) | $1,001 - $15,000 |
| 2023-05-30 | Lois Frankel | Purchase | $1,001 - $15,000 |
| 2023-05-01 | Lois Frankel | Sale (Partial) | $1,001 - $15,000 |
| 2023-04-26 | John Curtis | Sale (Partial) | $1,001 - $15,000 |
| 2023-04-21 | Michael McCaul | Sale | $15,001 - $50,000 |
| 2023-04-21 | Michael McCaul | Sale | $15,001 - $50,000 |
| 2023-04-19 | Lois Frankel | Sale (Partial) | $1,001 - $15,000 |
| 2023-04-05 | Michael McCaul | Sale | $15,001 - $50,000 |
| 2023-04-05 | Michael McCaul | Sale | $15,001 - $50,000 |
| 2023-03-29 | Lois Frankel | Sale (Partial) | $1,001 - $15,000 |
| 2023-03-27 | Michael McCaul | Sale | $50,001 - $100,000 |
| 2023-03-27 | Michael McCaul | Sale | $50,001 - $100,000 |
| 2023-02-23 | John Curtis | Sale (Partial) | $1,001 - $15,000 |
| 2022-12-16 | Michael McCaul | Sale | $1,001 - $15,000 |
| 2022-12-16 | Michael McCaul | Sale | $1,001 - $15,000 |
| 2022-12-07 | Michael McCaul | Sale | $15,001 - $50,000 |
| 2022-12-07 | Michael McCaul | Sale | $15,001 - $50,000 |
| 2022-11-03 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-10-24 | Alan S. Lowenthal | Sale (Full) | $1,001 - $15,000 |
| 2022-10-21 | Alan S. Lowenthal | Sale (Partial) | $1,001 - $15,000 |
| 2022-10-21 | Alan S. Lowenthal | Sale (Partial) | $1,001 - $15,000 |
| 2022-09-28 | Lois Frankel | Purchase | $1,001 - $15,000 |
| 2022-09-08 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-09-06 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-08-23 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-06-17 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-05-23 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2022-05-10 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-05-05 | Michael McCaul | Purchase | $15,001 - $50,000 |
| 2022-05-05 | Michael McCaul | Purchase | $15,001 - $50,000 |
| 2022-04-06 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2022-04-06 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-04-06 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2022-03-15 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-03-15 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-02-17 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-02-07 | Michael McCaul | Purchase | $1,001 - $15,000 |
| 2022-02-07 | Michael McCaul | Sale | $1,001 - $15,000 |
| 2022-02-07 | Michael McCaul | Purchase | $1,001 - $15,000 |
| 2022-02-07 | Michael McCaul | Sale | $1,001 - $15,000 |
| 2022-02-07 | Michael McCaul | Purchase | $50,001 - $100,000 |
| 2022-01-28 | Michael McCaul | Sale | $1,001 - $15,000 |
| 2022-01-28 | Michael McCaul | Sale | $15,001 - $50,000 |
| 2022-01-14 | Michael McCaul | Purchase | $50,001 - $100,000 |
| 2022-01-14 | Michael McCaul | Sale | $15,001 - $50,000 |
| 2022-01-14 | Michael McCaul | Purchase | $15,001 - $50,000 |
| 2022-01-14 | Michael McCaul | Sale | $50,001 - $100,000 |
| 2021-12-21 | Michael McCaul | Sale | $15,001 - $50,000 |
| 2021-12-16 | Robert J. Wittman | Sale (Full) | $1,001 - $15,000 |
| 2021-12-14 | Michael McCaul | Sale | $1,001 - $15,000 |
| 2021-07-21 | Kevin Hern | Purchase | $15,001 - $50,000 |
| 2021-07-01 | Kevin Hern | Purchase | $100,001 - $250,000 |
| 2021-06-22 | John Curtis | Purchase | $1,001 - $15,000 |
| 2021-05-20 | Kevin Hern | Purchase | $1,001 - $15,000 |
Recent news
- 2026-08-28 Boston Scientific (BSX) Up 1.5% Since Last Earnings Report: Can It Continue? Boston Scientific (BSX) reported earnings 30 days ago. What''s next for the stock?
- 2026-08-28 New Strong Sell Stocks for August 28th AU, APTV and BSX have been added to the Zacks Rank #5 (Strong Sell) List on August 28th, 2026.
- 2026-08-26 Stock Market Today, Aug. 26: Boston Scientific Shares Fall 5% on Cybersecurity Incident and Product Recall On Aug. 26, 2026, a cyberattack halted order processing and shipping at the medical device maker, leaving investors uncertain about the speed of recovery and near-term shipment delays.
- 2026-08-26 Boston Scientific Stock Slides After Cyberattack Caused ‘Global Disruption'' Boston Scientific''s stock is sliding in the wake of a major cyberattack, adding to its recent woes.
- 2026-08-26 Medical device maker Boston Scientific says a cyberattack is causing a ‘global disruption'' to its operations A cyberattack on U.S. medical device maker Boston Scientific is causing an ongoing “global disruption” to its operations, according to a federal regulatory filing on Wednesday, the latest healthtech giant to face a cyberattack in recent weeks.
- 2026-08-26 Boston Scientific Reports Global Disruption After Cybersecurity Incident On Tuesday, Boston Scientific Corporation (NYSE:BSX) identified a cybersecurity incident on Tuesday that caused global operational disruptions, including delays in processing and shipping customer orders.
- 2026-08-26 Why Boston Scientific Stock Crashed Today Boston Scientific said its global operations were disrupted by a "cybersecurity incident." The company also admitted its investigation was ongoing and the nature, scope, and impact of the incident had yet to be determined.
- 2026-08-26 Boston Scientific Stock Is Falling as Cyberattack Puts More Strain on the Medical Device Maker Boston Scientific stock falls as the medical device maker announces the latest batch of bad news for the company.
- 2026-08-26 Medical device maker Boston Scientific is being hit by a cyber attack. The shares are falling Boston Scientific was hit with a cyberattack that is affecting its operations, the company said Wednesday in an SEC filing. The attack is continuing to disrupt the company''s ability to ship products, and it''s not clear when services will be restored.
- 2026-08-26 Boston Scientific hit by cyberattack, global operations affected Boston Scientific said on Wednesday that a cybersecurity incident had disrupted global operations, including some information systems used to process and ship customer orders.